Violeta Serra (V Serra)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 44

Top Venues

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research

EMBO molecular medicine

Vall d'Hebron Institute of Oncology

Newcastle University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vall d'Hebron Institute of Oncology

Spain

Group Leader

Vall d'Hebron Institute of Oncology

Spain

Postdoc in Cancer Signalling and Targeted Therapeutics

Centro Nacional de Investigaciones Oncológicas

Spain

Postdoc in Cancer Signalling and Target Validation :: Experimental Therapeutics Program

Humboldt University of Berlin

Germany

Postdoc in Cancer Chemoresistance :: Institute of Pathology, Charité

Education History

Newcastle University

United Kingdom

PHD

IQS School of Engineering

Spain

MSC :: Department of Biochemistry

IQS School of Engineering

Spain

BSC

Publications

Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Alejandra Rezqallah, Sara Torres-Esquius, Alba Llop-Guevara, Mara Cruellas, María Teresa Martínez Martínez, Marcel Romey, Carsten Denkert, Violeta Serra, Isabel Chirivella, Judith Balmaña
Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing. JCO precision oncology 8 (2024)
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J Arenas, Helena Verdaguer, Fernando J Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, Joaquín Arribas, Orland Díez, Sara Gutiérrez-Enríquez, Josep V Forment, Mark J O'Connor, Mark Albertella, Judith Balmaña, Violeta Serra
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. Genome medicine 16 (1) (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J Arenas, Helena Verdaguer, Fernando J Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, Joaquín Arribas, Orland Díez, Sara Gutiérrez-Enríquez, Josep V Forment, Mark J O'Connor, Mark Albertella, Judith Balmaña, Violeta Serra
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. Genome medicine 16 (1) (2024)
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J Arenas, Helena Verdaguer, Fernando J Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, Joaquín Arribas, Orland Díez, Sara Gutiérrez-Enríquez, Josep V Forment, Mark J O'Connor, Mark Albertella, Judith Balmaña, Violeta Serra
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models. Genome medicine 16 (1) (2024)
Synnøve Yndestad, Christina Engebrethsen, Andrea Herencia-Ropero, Oleksii Nikolaienko, Olav K Vintermyr, Reidun K Lillestøl, Laura Minsaas, Beryl Leirvaag, Gjertrud T Iversen, Bjørnar Gilje, Egil S Blix, Helge Espelid, Steinar Lundgren, Jürgen Geisler, Hildegunn S Aase, Turid Aas, Einar G Gudlaugsson, Alba Llop-Guevara, Violeta Serra, Emilius A M Janssen, Per Eystein Lønning, Stian Knappskog, Hans Petter Eikesdal
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. JCO precision oncology 7 (2023)
Caroline E Gleason, Mark A Dickson, Mary E Klein Dooley, Cristina R Antonescu, Rodrigo Gularte-Mérida, Marimar Benitez, Juliana I Delgado, Raghu P Kataru, Mark Wei Yi Tan, Martina Bradic, Travis E Adamson, Kenneth P Seier, Allison L Richards, Marta Palafox, Eric Chan, Sandra P D' Angelo, Mrinal M Gounder, Mary Louise Keohan, Ciara M Kelly, Ping Chi, Sujana Movva, Jonathan Landa, Aimee M Crago, Mark T A Donoghue, Li-Xuan Qin, Violeta Serra, Mesruh Turkekul, Afsar Barlas, Daniel M Firester, Katia Manova, Babak J Mehrara, Marta Kovatcheva, Nguan Soon Tan, Samuel Singer, William D Tap, Andrew Koff
Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara Erika Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orrù, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli Romario, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F Amisano, Alessandro Ferrero, Caterina Marchio, Simona Corso, Silvia Giordano
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Cancer research 83 (10) (2023)
Laura Pascual-Reguant, Queralt Serra-Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Antoni Gañez Zapater, Chiara Cannatá, Maria Lorena Espinar Calvo, Jessica Querol, Laura García-López, Sara Musa-Afaneh, Maria Guirola, Anestis Gkanogiannis, Andrea Miró Canturri, Marta Guzman, Olga Rodríguez, Andrea Herencia-Ropero, Joaquín Arribas, Violeta Serra, Luis Serrano, Tian V Tian, Sandra Peiró, Sara Sdelci
Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer. EMBO molecular medicine (2023)
F Guffanti, M F Alvisi, A Anastasia, F Ricci, M Chiappa, A Llop-Guevara, Violeta Serra, R Fruscio, Andrea Degasperi, S Nik-Zainal, M R Bani, M Lupia, R Giavazzi, E Rulli, Giovanna Damia
Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. British journal of cancer (2023)
Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara Erika Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orrù, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli Romario, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F Amisano, Alessandro Ferrero, Caterina Marchio, Simona Corso, Silvia Giordano
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Cancer research 83 (10) (2023)
Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara Erika Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orrù, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli Romario, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F Amisano, Alessandro Ferrero, Caterina Marchio, Simona Corso, Silvia Giordano
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. Cancer research (2023)
Claire J H Kramer, Alba Llop-Guevara, Elisa Yaniz-Galende, Benedetta Pellegrino, Natalja T Ter Haar, Andrea Herencia-Ropero, Nicoletta Campanini, Antonino Musolino, Tjalling Bosse, Alexandra Leary, Violeta Serra, Maaike P G Vreeswijk
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test. The journal of pathology. Clinical research (2023)
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh C Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I Fisher, Eric T Gangl, Hilary J Lewis, Dawn Trueman, Neha Wali, Stuart Charles Williamson, Jennifer I Moss, Elodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas Moss, Gareth A Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E Critchlow, James S Scott, Justin P O Lindemann, Simon T Barry, Teresa Klinowska, Christopher J Morrow, Larissa S Carnevalli
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer research (2023)
Alistair Ring, Lucy Suzanne Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr, Andrew M Wardley, Bora Gurel, Iain R J Macpherson, Ruth Riisnaes, Richard D Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C Winter, Kathryn Dunne, Ellen R Copson, Tamas Hickish, Russell Burcombe, Kat Randle, Violeta Serra, Alba Llop-Guevara, Judith M Bliss, Nicholas C Turner
Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Amanda J Compadre, Lillian N van Biljon, Mark C Valentine, Alba Llop-Guevara, Emily Graham, Bisiayo Fashemi, Andrea Herencia-Ropero, Emilee N Kotnik, Isaac Cooper, Shariska P Harrington, Lindsay M Kuroki, Carolyn K McCourt, Andrea R Hagemann, Premal H Thaker, David G Mutch, Matthew A Powell, Lulu Sun, Nima Mosammaparast, Violeta Serra, Peinan Zhao, Elena Lomonosova, Dineo Khabele, Mary M Mullen
RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, Flaminia Pedretti, Alejandro Moles-Fernández, Cristina Viaplana, Guillermo Villacampa, Marta Guzmán, Olga Rodríguez, Judit Grueso, Jose Jiménez, Enrique J Arenas, Andrea Degasperi, Joao M L Dias, Josep V Forment, Lenka Oplustil O'Connor, Olivier Déas, Stefano Cairo, Yinghui Zhou, Antonino Musolino, Carlos Caldas, Serena Nik-Zainal, Robert B Clarke, Paolo G Nuciforo, Orland Díez, Xavier Serres-Créixams, Vicente Peg, Martín Espinosa-Bravo, Teresa Macarulla, Ana Oaknin, Joaquin Mateo, Joaquín Arribas, Rodrigo Dienstmann, Meritxell Bellet-Ezquerra, Mafalda Oliveira, Cristina Saura, Sara Gutiérrez-Enríquez, Judith Balmaña, Violeta Serra
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer research 82 (8) (2022)
Jennifer B Shah, Dana Pueschl, Bradley Wubbenhorst, Mengyao Fan, John Pluta, Kurt D'Andrea, Anna P Hubert, Jake S Shilan, Wenting Zhou, Adam A Kraya, Alba Llop Guevara, Catherine Ruan, Violeta Serra, Judith Balmaña, Michael Feldman, Pat J Morin, Anupma Nayak, Kara N Maxwell, Susan M Domchek, Katherine L Nathanson
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers. Nature communications 13 (1) (2022)
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J Pettitt, Krishna C Bulusu, Jenni Nikkilä, Zena Wilson, Adina M Hughes, Paul W G Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquín Arribas, Javier Cortes, Cristina Saura, Alan Lau, Susan E Critchlow, Brian Dougherty, Carlos Caldas, Gordon B Mills, J Carl Barrett, Josep V Forment, Elaine B Cadogan, Christopher J Lord, Cristina Cruz, Judith Balmaña, Lenka Oplustil O'Connor
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (20) (2022)
Roberto Dinami, Luca Pompili, Eleonora Petti, Manuela Porru, Carmen D'Angelo, Serena Di Vito, Angela Rizzo, Virginia Campani, Giuseppe De Rosa, Alejandra Bruna, Violeta Serra, Miguel Mano, Mauro Giacca, Carlo Leonetti, Gennaro Ciliberto, Madalena Tarsounas, Antonella Stoppacciaro, Stefan Schoeftner, Annamaria Biroccio
MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer. EMBO molecular medicine (2022)
Daniel Massó-Vallés, Marie-Eve Beaulieu, Toni Jauset, Fabio Giuntini, Mariano F Zacarias-Fluck, Laia Foradada, Sandra Martínez-Martín, Erika Serrano, Génesis Martín-Fernández, Sílvia Casacuberta-Serra, Virginia Castillo Cano, Jastrinjan Kaur, Sergio López-Estévez, Miguel Ángel Morcillo Alonso, Mohammad Alzrigat, Loay Mahmoud, Antonio Luque, Marta Escorihuela, Marta Guzman, Joaquín Arribas, Violeta Serra, Lars-Gunnar Larsson, Jonathan R Whitfield, Laura Soucek
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer research communications 2 (2) (2022)
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Nuria Lopez-Bigas, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández-Losa, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo G Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Núria López-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nature communications 13 (1) (2022)
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Nuria Lopez-Bigas, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández-Losa, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo G Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Núria López-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. Nature communications 13 (1) (2022)
Shanade Dunn, Cath Eberlein, Jason Yu, Albert Gris-Oliver, Swee Hoe Ong, Urs Yelland, Natalie Cureton, Anna Staniszewska, Robert McEwen, Millie Fox, James Pilling, Philip Hopcroft, Elizabeth A Coker, Patricia Jaaks, Mathew J Garnett, Beverley Isherwood, Violeta Serra, Barry R Davies, Simon T Barry, James T Lynch, Kosuke Yusa
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene 41 (46) (2022)
Florian J Groelly, Manuela Porru, Jutta Zimmer, Hugo Benainous, Yanti De Visser, Anastasiya A Kosova, Serena Di Vito, Violeta Serra, Anderson Ryan, Carlo Leonetti, Alejandra Bruna, Annamaria Biroccio, Madalena Tarsounas
Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. EMBO molecular medicine 14 (3) (2022)
Daniel Massó-Vallés, Marie-Eve Beaulieu, Toni Jauset, Fabio Giuntini, Mariano F Zacarias-Fluck, Laia Foradada, Sandra Martínez-Martín, Erika Serrano, Génesis Martín-Fernández, Sílvia Casacuberta-Serra, Virginia Castillo Cano, Jastrinjan Kaur, Sergio López-Estévez, Miguel Ángel Morcillo Alonso, Mohammad Alzrigat, Loay Mahmoud, Antonio Luque, Marta Escorihuela, Marta Guzman, Joaquín Arribas, Violeta Serra, Lars-Gunnar Larsson, Jonathan R Whitfield, Laura Soucek
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer research communications 2 (2) (2022)
Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J Arenas Lahuerta, Cristina Bernadó Bernadó Morales, Noemí Haro, Francis J Giles, Oscar J Pozo, Josep M Miquel, Paolo G Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquín Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V Tian
Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, George Seed, Alba Llop-Guevara, Diletta Bianchini, Pasquale Rescigno, Alec Paschalis, Claudia Bertan, Chloe Baker, Jane Goodall, Susana Miranda, Ruth Riisnaes, Ines Figueiredo, Ana Ferreira, Rita Pereira, Mateus Crespo, Bora Gurel, Daniel Nava Rodrigues, Stephen J Pettitt, Wei Yuan, Violeta Serra, Jan Rekowski, Christopher J Lord, Emma C Hall, Joaquin Mateo, Johann S de Bono
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer discovery 11 (11) (2021)
Dimitra Georgopoulou, Maurizio Callari, Oscar M Rueda, Abigail Shea, Alistair Martin, Agnese Giovannetti, Fatime Qosaj, Ali Dariush, Suet-Feung Chin, Larissa S Carnevalli, Elena Provenzano, Wendy Greenwood, Giulia Lerda, Elham Esmaeilishirazifard, Martin O'Reilly, Violeta Serra, Dario Bressan, null null, Gordon B Mills, H Raza Ali, Sabina S Cosulich, Gregory J Hannon, Alejandra Bruna, Carlos Caldas
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature communications 12 (1) (2021)
Albert Gris-Oliver, Yasir H Ibrahim, Martín A Rivas, Celina García-García, Mònica Sánchez-Guixé, Fiorella Ruiz-Pace, Cristina Viaplana, José M Pérez-García, Antonio Llombart-Cussac, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Pilar Anton, Patricia Cozar, Maria Teresa Calvo, Alejandra Bruna, Joaquín Arribas, Carlos Caldas, Rodrigo Dienstmann, Paolo Nuciforo, Mafalda Oliveira, Javier Cortes, Violeta Serra
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. British journal of cancer 124 (9) (2021)
Xing Yi Woo, Jessica Giordano, Anuj Srivastava, Zi-Ming Zhao, Michael W Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Rajesh Patidar, Li Chen, Sandra Scherer, Matthew H Bailey, Chieh-Hsiang Yang, Emilio Cortes-Sanchez, Yuanxin Xi, Jing Wang, Jayamanna Wickramasinghe, Andrew V Kossenkov, Vito W Rebecca, Hua Sun, R Jay Mashl, Sherri R Davies, Ryan Jeon, Christian Frech, Jelena Randjelovic, Jacqueline Rosains, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C O'Farrell, Elodie Modave, Diether Lambrechts, Petra Ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Hyunsoo Kim, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A Dean, Brandi Davis-Dusenbery, Yvonne A Evrard, James H Doroshow, Alana L Welm, Bryan E Welm, Michael T Lewis, Bingliang Fang, Jack A Roth, Funda Meric-Bernstam, Meenhard Herylyn, Michael A Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Claudio Isella, Jeffrey A Moscow, Livio Trusolino, Annette T Byrne, Jos Jonkers, Carol J Bult, Enzo Medico, Jeffrey H Chuang, null null, null null
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature genetics 53 (1) (2021)
Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo G Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
F Guffanti, M F Alvisi, A Anastasia, F Ricci, M Chiappa, A Llop-Guevara, Violeta Serra, R Fruscio, Andrea Degasperi, S Nik-Zainal, M R Bani, M Lupia, R Giavazzi, E Rulli, Giovanna Damia
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. British journal of cancer (2021)
Qing Li, Baishan Jiang, Jiaye Guo, Hong Shao, Isabella S Del Priore, Qing Chang, Rei Kudo, Zhiqiang Li, Pedram Razavi, Bo Liu, Andrew S Boghossian, Matthew G Rees, Melissa A Ronan, Jennifer A Roth, Katherine Aleisha Donovan, Marta Palafox, Jorge S Reis-Filho, Elisa de Stanchina, Eric S Fischer, Neal X Rosen, Violeta Serra, Andrew Koff, John D Chodera, Nathanael S Gray, Sarat Chandarlapaty
INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer discovery (2021)
Álvaro Lahiguera, Petra Hyroššová, Agnès Figueras, Diana Garzón, Roger Moreno, Vanessa Soto-Cerrato, Iain McNeish, Violeta Serra, Conxi Lazaro, Pilar Barretina, Joan Brunet, Javier Menéndez, Xavier Matias-Guiu, August Vidal, Alberto Villanueva, Barbie Taylor-Harding, Hisashi Tanaka, Sandra Orsulic, Alexandra Junza, Oscar Yanes, Cristina Muñoz-Pinedo, Luís Palomero, Miquel Àngel Pujana, José Carlos Perales, Francesc Viñals
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. EMBO molecular medicine 12 (6) (2020)
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S Hirst, Alan Barnicle, Elza C de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo G Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C Turner, Cristina Saura, Barry R Davies, Mafalda Oliveira, Violeta Serra
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (14) (2020)
Jorge Gómez-Miragaya, Ander Díaz-Navarro, Raul Tonda, Sergi Beltran, Luis Palomero, Marta Palafox, Lacey E Dobrolecki, Chen Huang, Suhas Vasaikar, Bing Zhang, Gerburg M Wulf, Alejandro Collado-Sole, Eva María Trinidad, Purificación Muñoz, Laia Paré, Aleix Prat, Alejandra Bruna, Carlos Caldas, Joaquín Arribas, María Teresa Soler-Monso, Anna Petit, Judith Balmaña, Cristina Cruz, Violeta Serra, Miguel Angel Pujana, Michael T Lewis, Xose S Puente, Eva González-Suárez
Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer research 79 (16) (2019)
Jorge Gómez-Miragaya, Sebastián Morán, Maria Eréndira Calleja-Cervantes, Alejandro Collado-Sole, Laia Paré, Antonio Gómez, Violeta Serra, Lacey E Dobrolecki, Michael T Lewis, Angel Diaz-Lagares, Pilar Eroles, Aleix Prat, Manel Esteller, Eva González-Suárez
The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular cancer research : MCR 17 (10) (2019)
Yifan Wang, Andrea J Bernhardy, Joseph Nacson, John J Krais, Yin-Fei Tan, Emmanuelle Nicolas, Marc R Radke, Elizabeth Handorf, Alba Llop-Guevara, Judith Balmaña, Elizabeth M Swisher, Violeta Serra, Suraj Peri, Neil Johnson
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nature communications 10 (1) (2019)
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles-Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Maria Vidal, Vicente Peg, Xavier Serres-Créixams, Graham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T Rubio, Rodrigo Dienstmann, J Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean-Yves Masson, Stefano Cairo, Jean-Gabriel Judde, Mark J O'Connor, Orland Díez, Judith Balmaña, Violeta Serra
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO molecular medicine 10 (12) (2019)
Harveer Dev, Ting-Wei Will Chiang, Chloe Lescale, Inge de Krijger, Alistair G Martin, Domenic Pilger, Julia Coates, Matylda Sczaniecka-Clift, Wenming Wei, Matthias Ostermaier, Mareike Herzog, Jonathan Lam, Abigail Shea, Mukerrem Demir, Qian Wu, Fengtang Yang, Beiyuan Fu, Zhongwu Lai, Gabriel Balmus, Rimma Belotserkovskaya, Violeta Serra, Mark J O'Connor, Alejandra Bruna, Petra Beli, Luca Pellegrini, Carlos Caldas, Ludovic Deriano, Jacqueline J L Jacobs, Yaron Galanty, Stephen P Jackson
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nature cell biology 20 (8) (2018)
Ivana Zagorac, Sara Fernandez-Gaitero, Renske Penning, Harm Post, Maria J Bueno, Silvana Mouron, Luis Manso Sanchez, Manuel M Morente, Soledad Alonso, Violeta Serra, Javier Muñoz, Gonzalo Gómez-López, Jose Francisco Lopez-Acosta, Veronica Jimenez-Renard, Albert Gris-Oliver, Fatima Al-Shahrour, Elena Piñeiro-Yañez, Jose Luis Montoya-Suarez, Juan V Apala, Amalia Moreno-Torres, Ramon Colomer, Ana Dopazo, Albert J R Heck, Maarten Altelaar, Miguel Quintela-Fandino
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nature communications 9 (1) (2018)

Violeta Serra.css-eqlu8i{font-size:small;padding-left:4px;} (V Serra)

Publication Activity (10 Years)

Top Topics

Top Venues

Violeta Serra (V Serra)